Top 5 Undervalued Stocks To Buy Right Now

Tupperware Brands’ (NYSE:TUP) stock has tumbled more than 40% since last July on a consistent flow of negative news. Most recently, TUP revised its first-quarter earnings forecast down by 14% to $0.87-0.92 from a previous range of $1.01-1.06. Customer service, supply chain, and tax issues were the main reasons for the revision. With that being said, I see the stock as being significantly undervalued for the following reasons:

Free cash flow is expected to rebound to $170-180 million in 2018, an increase of approximately $30 million over 2017. Free cash flow should further rebound in future years as TUP completes its reengineering program. This yields 51% upside potential in a conservative discounted cash flow model. TUP is performing well in Emerging Markets, especially China and Brazil, which could push TUP to a growth trajectory in the coming years. The company currently has a dividend yield of 6.52%, which is supported by free cash flow. Based on TUP’s 2018 free cash flow projection, this should equal dividend coverage of approximately 80%. It has attractive fundamental valuations including a Forward P/E of 8.51x and a PEG of 0.73x. Tupperware Brands’ Operations

Driving TUP’s net loss for 2017 was a number of non-recurring expenses:

Top 5 Undervalued Stocks To Buy Right Now: Zogenix, Inc.(ZGNX)

Advisors’ Opinion:

  • [By Sean Williams]

    Back in September, drug developer Zogenix (NASDAQ:ZGNX) announced data from ZX008 in late-stage trials that absolutely wowed Wall Street. ZX008, which is a low-dose fenfluramine, led to a 72.4% reduction in seizure frequency from baseline over a 14-week testing period. This compared very favorably with a 17.4% reduction in seizure frequency from baseline observed with the placebo.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Zogenix (ZGNX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Sean Williams]

    The other concern is that while it may be the first to market in treating Dravet syndrome and Lennox-Gastaut syndrome, another experimental therapy is nipping at its heels. In September, Zogenix (NASDAQ:ZGNX) announced surprisingly strong phase 3 data for ZX008, a low-dose fenfluramine that absolutely blew away the placebo in Dravet syndrome patient testing. Zogenix’s lead compound led to a 72.4% reduction in convulsive seizure frequency over a 14-week period, compared to the 17.4% reduction for placebo patients.

Top 5 Undervalued Stocks To Buy Right Now: Greenhill & Co., Inc.(GHL)

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Greenhill & Co. (GHL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Greenhill & Co. (NYSE: GHL) is one of 31 publicly-traded companies in the “Security brokers & dealers” industry, but how does it compare to its competitors? We will compare Greenhill & Co. to related businesses based on the strength of its valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Top 5 Undervalued Stocks To Buy Right Now: Culp, Inc.(CFI)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Cofound.it (CURRENCY:CFI) traded down 2.1% against the U.S. dollar during the 24-hour period ending at 21:00 PM Eastern on May 12th. In the last week, Cofound.it has traded down 21% against the U.S. dollar. One Cofound.it token can currently be purchased for about $0.0769 or 0.00000911 BTC on major exchanges including Liqui, IDEX, HitBTC and Upbit. Cofound.it has a total market capitalization of $25.01 million and approximately $314,252.00 worth of Cofound.it was traded on exchanges in the last day.

Top 5 Undervalued Stocks To Buy Right Now: Dawson Geophysical Company(DWSN)

Advisors’ Opinion:

  • [By Logan Wallace]

    Dawson Geophysical (NASDAQ:DWSN) was upgraded by stock analysts at TheStreet from a “d+” rating to a “c-” rating in a research note issued on Monday.

Top 5 Undervalued Stocks To Buy Right Now: Cumberland Pharmaceuticals Inc.(CPIX)

Advisors’ Opinion:

  • [By Max Byerly]

    COPYRIGHT VIOLATION NOTICE: “Cumberland Pharmaceuticals (CPIX) Research Coverage Started at B. Riley” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/3364464/cumberland-pharmaceuticals-cpix-research-coverage-started-at-b-riley.html.